Sagent Pharmaceuticals Reports Second Quarter 2012 Financial Results
Sagent Pharmaceuticals (NASDAQ: SGNT), today announced financial results for the quarter ended June 30, 2012.
Second Quarter 2012 Highlights:
Revenue increased 32% to $42.7 million driven by products launched in the last twelve months;
Reported gross profit increased to $6.5 million, or 15.2% inclusive of $1.2 million of margin from the sale of heparin inventory previously written off through excess inventory reserves;
Launched Atracurium Besylate and Irinotecan; and
Key manufacturing partner's facility found acceptable by FDA, clearing pathway for multiple product approvals and four to six new product launches during the second half of 2012.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.